IGC Pharma (IGC) announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA Phase 2 clinical trial, investigating IGC-AD1 for agitation in Alzheimer’s disease. This strategic site directly addresses the significant impact of Alzheimer’s in the region.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGC:
- IGC Pharma presents genetic toxicology safety data on IGC-AD1
- IGC Pharma announces strategic investment from advisors
- IGC Pharma expands CALMA trial with addition of Butler Hospital Program
- IGC Pharma announces CALMA Phase 2 trial expansion with Miami Jewish Health
- IGC Pharma expands CALMA clinical trial